These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 29485864)

  • 21. Discovery of imidazo[1,2-a]-pyridine inhibitors of pan-PI3 kinases that are efficacious in a mouse xenograft model.
    Han W; Menezes DL; Xu Y; Knapp MS; Elling R; Burger MT; Ni ZJ; Smith A; Lan J; Williams TE; Verhagen J; Huh K; Merritt H; Chan J; Kaufman S; Voliva CF; Pecchi S
    Bioorg Med Chem Lett; 2016 Feb; 26(3):742-746. PubMed ID: 26774655
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis, biological evaluation and molecular modeling studies of imidazo[1,2-a]pyridines derivatives as protein kinase inhibitors.
    Lawson M; Rodrigo J; Baratte B; Robert T; Delehouzé C; Lozach O; Ruchaud S; Bach S; Brion JD; Alami M; Hamze A
    Eur J Med Chem; 2016 Nov; 123():105-114. PubMed ID: 27474927
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design, Synthesis, and Pharmacological Evaluation of Novel Multisubstituted Pyridin-3-amine Derivatives as Multitargeted Protein Kinase Inhibitors for the Treatment of Non-Small Cell Lung Cancer.
    Zhu W; Chen H; Wang Y; Wang J; Peng X; Chen X; Gao Y; Li C; He Y; Ai J; Geng M; Zheng M; Liu H
    J Med Chem; 2017 Jul; 60(14):6018-6035. PubMed ID: 28714692
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Coordinated ubiquitination and phosphorylation of RIP1 regulates necroptotic cell death.
    de Almagro MC; Goncharov T; Izrael-Tomasevic A; Duttler S; Kist M; Varfolomeev E; Wu X; Lee WP; Murray J; Webster JD; Yu K; Kirkpatrick DS; Newton K; Vucic D
    Cell Death Differ; 2017 Jan; 24(1):26-37. PubMed ID: 27518435
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design, synthesis and evaluation of novel 2-(1H-imidazol-2-yl) pyridine Sorafenib derivatives as potential BRAF inhibitors and anti-tumor agents.
    Jiao Y; Xin BT; Zhang Y; Wu J; Lu X; Zheng Y; Tang W; Zhou X
    Eur J Med Chem; 2015 Jan; 90():170-83. PubMed ID: 25461318
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Optimization and in vivo evaluation of pyrazolopyridines as a potent and selective PI3Kδ inhibitor.
    Hamajima T; Takahashi F; Kato K; Sugano Y; Yamaki S; Moritomo A; Kubo S; Nakamura K; Yamagami K; Hamakawa N; Yokoo K; Fukahori H
    Bioorg Med Chem; 2018 Aug; 26(14):3917-3924. PubMed ID: 29907471
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery, synthesis, and characterization of an orally bioavailable, brain penetrant inhibitor of mixed lineage kinase 3.
    Goodfellow VS; Loweth CJ; Ravula SB; Wiemann T; Nguyen T; Xu Y; Todd DE; Sheppard D; Pollack S; Polesskaya O; Marker DF; Dewhurst S; Gelbard HA
    J Med Chem; 2013 Oct; 56(20):8032-48. PubMed ID: 24044867
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discovery of a novel and potent series of thieno[3,2-b]pyridine-based inhibitors of c-Met and VEGFR2 tyrosine kinases.
    Claridge S; Raeppel F; Granger MC; Bernstein N; Saavedra O; Zhan L; Llewellyn D; Wahhab A; Deziel R; Rahil J; Beaulieu N; Nguyen H; Dupont I; Barsalou A; Beaulieu C; Chute I; Gravel S; Robert MF; Lefebvre S; Dubay M; Pascal R; Gillespie J; Jin Z; Wang J; Besterman JM; MacLeod AR; Vaisburg A
    Bioorg Med Chem Lett; 2008 May; 18(9):2793-8. PubMed ID: 18434145
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel imidazo[1,2-a]pyridine based inhibitors of the IGF-1 receptor tyrosine kinase: optimization of the aniline.
    Ducray R; Jones CD; Jung FH; Simpson I; Curwen J; Pass M
    Bioorg Med Chem Lett; 2011 Aug; 21(16):4702-4. PubMed ID: 21764307
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design, synthesis, and docking studies of phenylpicolinamide derivatives bearing 1H-pyrrolo[2,3-b]pyridine moiety as c-Met inhibitors.
    Zhu W; Wang W; Xu S; Tang Q; Luo R; Wang M; Gong P; Zheng P
    Bioorg Med Chem; 2016 Feb; 24(4):812-9. PubMed ID: 26810712
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synthesis and pharmacological evaluation of thieno[2,3-b]pyridine derivatives as novel c-Src inhibitors.
    Pevet I; Brulé C; Tizot A; Gohier A; Cruzalegui F; Boutin JA; Goldstein S
    Bioorg Med Chem; 2011 Apr; 19(8):2517-28. PubMed ID: 21459579
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery of novel 2-substituted-4-(2-fluorophenoxy) pyridine derivatives possessing pyrazolone and triazole moieties as dual c-Met/VEGFR-2 receptor tyrosine kinase inhibitors.
    Gu W; Dai Y; Qiang H; Shi W; Liao C; Zhao F; Huang W; Qian H
    Bioorg Chem; 2017 Jun; 72():116-122. PubMed ID: 28411406
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discovery of a First-in-Class Receptor Interacting Protein 1 (RIP1) Kinase Specific Clinical Candidate (GSK2982772) for the Treatment of Inflammatory Diseases.
    Harris PA; Berger SB; Jeong JU; Nagilla R; Bandyopadhyay D; Campobasso N; Capriotti CA; Cox JA; Dare L; Dong X; Eidam PM; Finger JN; Hoffman SJ; Kang J; Kasparcova V; King BW; Lehr R; Lan Y; Leister LK; Lich JD; MacDonald TT; Miller NA; Ouellette MT; Pao CS; Rahman A; Reilly MA; Rendina AR; Rivera EJ; Schaeffer MC; Sehon CA; Singhaus RR; Sun HH; Swift BA; Totoritis RD; Vossenkämper A; Ward P; Wisnoski DD; Zhang D; Marquis RW; Gough PJ; Bertin J
    J Med Chem; 2017 Feb; 60(4):1247-1261. PubMed ID: 28151659
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design, synthesis, and molecular docking study of 3H-imidazole[4,5-c]pyridine derivatives as CDK2 inhibitors.
    Wu YZ; Ying HZ; Xu L; Cheng G; Chen J; Hu YZ; Liu T; Dong XW
    Arch Pharm (Weinheim); 2018 Jun; 351(6):e1700381. PubMed ID: 29708285
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design, synthesis, biological evaluation and molecular modeling of novel 2-amino-4-(1-phenylethoxy) pyridine derivatives as potential ROS1 inhibitors.
    Tian Y; Zhang T; Long L; Li Z; Wan S; Wang G; Yu Y; Hou J; Wu X; Zhang J
    Eur J Med Chem; 2018 Jan; 143():182-199. PubMed ID: 29174814
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cell division cycle 7 kinase inhibitors: 1H-pyrrolo[2,3-b]pyridines, synthesis and structure-activity relationships.
    Ermoli A; Bargiotti A; Brasca MG; Ciavolella A; Colombo N; Fachin G; Isacchi A; Menichincheri M; Molinari A; Montagnoli A; Pillan A; Rainoldi S; Sirtori FR; Sola F; Thieffine S; Tibolla M; Valsasina B; Volpi D; Santocanale C; Vanotti E
    J Med Chem; 2009 Jul; 52(14):4380-90. PubMed ID: 19555113
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery and optimization of N-acyl and N-aroylpyrazolines as B-Raf kinase inhibitors.
    Blackburn C; Duffey MO; Gould AE; Kulkarni B; Liu JX; Menon S; Nagayoshi M; Vos TJ; Williams J
    Bioorg Med Chem Lett; 2010 Aug; 20(16):4795-9. PubMed ID: 20630752
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synthesis and SAR of new pyrazolo[4,3-h]quinazoline-3-carboxamide derivatives as potent and selective MPS1 kinase inhibitors.
    Caldarelli M; Angiolini M; Disingrini T; Donati D; Guanci M; Nuvoloni S; Posteri H; Quartieri F; Silvagni M; Colombo R
    Bioorg Med Chem Lett; 2011 Aug; 21(15):4507-11. PubMed ID: 21723120
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synthesis and bioevaluation and doking study of 1H-pyrrolo[2,3-b]pyridine derivatives bearing aromatic hydrazone moiety as c-Met inhibitors.
    Wang W; Xu S; Duan Y; Liu X; Li X; Wang C; Zhao B; Zheng P; Zhu W
    Eur J Med Chem; 2018 Feb; 145():315-327. PubMed ID: 29331754
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cellular IAP proteins and LUBAC differentially regulate necrosome-associated RIP1 ubiquitination.
    de Almagro MC; Goncharov T; Newton K; Vucic D
    Cell Death Dis; 2015 Jun; 6(6):e1800. PubMed ID: 26111062
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.